OABIW

Insider Trades

Name	Value	Action	Price	Current Price
Foehr Matthew WDirector, Officer: President And CEO $29k19.2k shares SellApr 7, 2026 $1.49 $0.062
Berkman Charles SChief Legal Officer $11k7.2k shares SellApr 7, 2026 $1.49 $0.062
Gustafson Kurt AExecutive VP, Finance And CFO $10k6.9k shares SellApr 7, 2026 $1.49 $0.062
Foehr Matthew WDirector, Officer: President And CEO $53k30.8k shares SellFeb 18, 2026 $1.71 $0.062
Berkman Charles SChief Legal Officer $17k9.7k shares SellFeb 18, 2026 $1.71 $0.062
Gustafson Kurt AExecutive VP, Finance And CFO $16k9.3k shares SellFeb 18, 2026 $1.71 $0.062

Trade OABIW

About OmniAb, Inc.

OmniAb, Inc., established in 2012 and headquartered in Emeryville, California, operates as a biotechnology firm focused on pioneering technologies for the discovery of therapeutic antibodies within the United States. The company's flagship offering is its OmniAb platform, which provides industry collaborators with access to a broad spectrum of antibody repertoires and advanced screening techniques. This capability empowers partners to develop next-generation therapeutic agents. At the heart of the OmniAb platform are proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse. These animals have been genetically engineered to produce antibodies featuring human sequences, thereby streamlining the path to creating human therapeutic candidates. Beyond this core offering, OmniAb also addresses specific industry needs with specialized animal models: OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken) facilitate bispecific antibody applications through a shared light chain mechanism. Additionally, OmniTaur provides a solution for challenging targets by leveraging the distinctive structural characteristics of cow antibodies.

CEO: Matthew W. Foehr
IPO Date: Sep 30, 2021

Market Data

Open: $0.1182
High: $0.1183
Low: $0.1168
Volume: 570
Avg Volume: 3.8K
52W High: $0.165
52W Low: $0.0532

Valuation

Market Cap: $283.4M
Enterprise Value: $269.3M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$37M
Revenue: $18.7M
Net Income: -$64.8M
Cash: $25.5M
Debt: $20.3M

Events

EarningsAug 6

EPS est. -0.12